Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/CIMA-AEMPS/EVUSHELD 150 MG +150 MG SOLUCION INYECTABLE

Approved

STANDARD

EVUSHELD 150 MG +150 MG SOLUCION INYECTABLE

Astrazeneca Ab🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Mar 31, 2022
Approval ID: 01446d1258f1d211
Company: Astrazeneca Ab
Type: Standard

Approval Details

Approval Id: 01446d1258f1d211
Drug Cima Aemps Name: EVUSHELD 150 MG +150 MG SOLUCION INYECTABLE
Register Number: 1221651001
Holder Company Name: Astrazeneca Ab
Marketing Company Name: Astrazeneca Farmaceutica Spain S.A.
Holder Company Detail Path: /organization/astrazeneca-ab
Authorization Date: 2022-03-31
Dosage Form: SOLUCIÓN INYECTABLE
Dose: 150 MG+150 MG
Route Of Administration: VÍA INTRAMUSCULAR
Prescription Type: Diagnóstico Hospitalario
Commercialized: No
Company Name: Astrazeneca Ab
Company Detail Path: /organization/astrazeneca-ab

Company Information

Pharmaceutical Company Name: ASTRAZENECA AB
Country Name: Spain
City Name: madrid,madrid,country_es
Address: CALLE RAIMUNDO FERNANDEZ VILLAVERDE 63
Website: http://www.astrazeneca.se

Active Ingredients

TIXAGEVIMAB

150 mg

CILGAVIMAB

150 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Mar 31, 2022

Approval ID

01446d1258f1d211

Type

Standard

Back to CIMA-AEMPS Approvals

EVUSHELD 150 MG +150 MG SOLUCION INYECTABLE - CIMA-AEMPS Drug Approval Details